Expert dermatologists review the validated investigator global assessment for AD (vIGA-AD) response in the ADORING 1 and ADORING 2 trials for tapinarof.
This is a video synopsis/summary of a panel discussion involving Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD.
In a recent discussion about a therapeutic approach for managing itch in patients with atopic dermatitis, the focus was on presenting data in a way that's understandable to both healthcare providers and patients. The speaker highlighted the importance of addressing itch, especially in the younger age group, as it is associated with sleep disruption, impacting both the child and the family. The goal of the therapy discussed was to achieve significant itch relief, emphasizing its role in enhancing the quality of life for patients.
The conversation delved into the data, pointing out the differentiation observed at 24 hours and significant improvements seen at 2 weeks, with more than half of individuals experiencing meaningful relief by the end of week 8. The speaker underscored the positive impact of controlling itching early and consistently throughout a clinical trial, leading to statistically significant improvements compared to the vehicle response. The overarching objective was to make patients more comfortable by effectively managing itch, a key aspect in aiding patients with atopic dermatitis.
The discussion then shifted to the efficacy data, particularly focusing on the Investigator Global Assessment (IGA) metrics for atopic dermatitis. The data indicated remarkable improvements in both ADORING 1 and ADORING 2 groups, with statistically significant deltas compared to the vehicle. The speaker highlighted the consistency across different age groups, expressing excitement about the dataset and its potential impact on future treatment options. The hope for FDA approval in early 2024 was mentioned optimistically.
The conversation concluded by addressing the practicality of the therapy, emphasizing the ease of application with once-a-day usage and a positive perspective on the patient compliance achieved. The speaker acknowledged the trial's moderate slant, with a majority of patients being in the moderate category, and discussed how the results stacked up well for this group. The therapy was positioned as a potential sweet spot for patients in the moderate range, providing a valuable option in the realm of atopic dermatitis treatment.
Video synopsis is AI-generated and reviewed by Dermatology Times editorial staff.